How to buy NanoVibronix stock

NanoVibronix, Inc is a medical devices business based in the US. NanoVibronix shares (NAOV) are listed on the NASDAQ and all prices are listed in US Dollars. NanoVibronix employs 11 staff and has a trailing 12-month revenue of around 0.00.

NanoVibronix share price

Use our graph to track the performance of NAOV stocks over time.

NanoVibronix shares at a glance

• Key figures

Information last updated 2021-04-21.

52-week range	$0.54 - $2.49
50-day moving average	$1.04
200-day moving average	$0.95
Wall St. target price	$10.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.92

Buy NanoVibronix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NanoVibronix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NanoVibronix, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NanoVibronix financials

Revenue TTM	$623,000
Gross profit TTM	$214,000
Return on assets TTM	-57.47%
Return on equity TTM	-231.16%
Profit margin	0%
Book value	$0.11
Market capitalisation	$20.5 million

TTM: trailing 12 months

Shorting NanoVibronix shares

There are currently 161,288 NanoVibronix shares held short by investors – that's known as NanoVibronix's "short interest". This figure is 34.6% down from 246,662 last month.

There are a few different ways that this level of interest in shorting NanoVibronix shares can be evaluated.

NanoVibronix's "short interest ratio" (SIR)

NanoVibronix's "short interest ratio" (SIR) is the quantity of NanoVibronix shares currently shorted divided by the average quantity of NanoVibronix shares traded daily (recently around 1.0 million). NanoVibronix's SIR currently stands at 0.16. In other words for every 100,000 NanoVibronix shares traded daily on the market, roughly 160 shares are currently held short.

However NanoVibronix's short interest can also be evaluated against the total number of NanoVibronix shares, or, against the total number of tradable NanoVibronix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NanoVibronix's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 NanoVibronix shares in existence, roughly 10 shares are currently held short) or 0.0067% of the tradable shares (for every 100,000 tradable NanoVibronix shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NanoVibronix.

Find out more about how you can short NanoVibronix stock.

NanoVibronix share dividends

We're not expecting NanoVibronix to pay a dividend over the next 12 months.

NanoVibronix share price volatility

Over the last 12 months, NanoVibronix's shares have ranged in value from as little as $0.5351 up to $2.4887. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NanoVibronix's is -0.1936. This would suggest that NanoVibronix's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NanoVibronix has bucked the trend.

NanoVibronix overview

NanoVibronix, Inc. , through its subsidiary, NanoVibronix Ltd. , focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

Frequently asked questions

• What percentage of NanoVibronix is owned by insiders or institutions?

  Currently 12.151% of NanoVibronix shares are held by insiders and 9.007% by institutions.

• How many people work for NanoVibronix?

  Latest data suggests 11 work at NanoVibronix.

• When does the fiscal year end for NanoVibronix?

  NanoVibronix's fiscal year ends in December.

• Where is NanoVibronix based?

  NanoVibronix's address is: 525 Executive Boulevard, Elmsford, NY, United States, 10523

• What is NanoVibronix's ISIN number?

  NanoVibronix's international securities identification number is: US63008J1088

• What is NanoVibronix's CUSIP number?

  NanoVibronix's Committee on Uniform Securities Identification Procedures number is: 63008J108